-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Malignant pleural effusion (MPE) is the fluid between the pleural wall and internal organs such as the lungs.
According to the research published by him and his colleagues in Nature Nanotechnology, some clinical trials are currently adopting immune checkpoint inhibitors and some new immunotherapies to help treat MPE.
Some clinical samples of MPE showed part of the reason.
In the eyes of Dr.
▲Nanoparticles can target macrophages in pleural effusion (picture source: reference [2])
The essence of this kind of nanoparticle is some tiny lipid particles, and it is loaded with cyclic dinucleotide (CDN), which can activate the interferon-related signal pathway of macrophages and dendritic cells after entering the pleural effusion
In the MPE mouse model, after they injected these nanoparticles into the chest cavity, the transcriptome of the cells in the pleural effusion began to change
The research team tried to use this kind of nanoparticles in combination with immunotherapy.
In addition to mice, the researchers selected some samples of MPE patients as preclinical tests.
Note: The original text has been deleted
Reference materials:
[1] Dawen Zhao, Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion, Nature Nanotechnology (2021).
[2] Nanoparticle therapeutic enhances cancer immunotherapy.
